RE:RE:RE:eyes on the prize20+ year old single product company Immunomedics was purchased by Gilead for US$21 Billion 2 years ago.
Multibillion dollar acquisitions are becoming the standard in a current environment where Big Pharma has US$1.5 Trillion in firepower, a looming patent cliff, and a dwindling product pipeline that requires replenishment with biological products over small molecules.
I am getting the distinct impression that Geneman is here to soft bash ONCY and the environment that ONCY is positioned in, without knowing much aabout what he is saying.